Mol Cell Endocrinol 297:137140 30 (7) Lau JF, Anderson AS, Bloch P, Lau J, Garibay PW , Kruse T, Jessen CU
They found that those taking GLP-1R agonists in the six months before their COVID-19 diagnosis were much less likely to suffer severe complications from the disease in comparison to those of a similar age, race, ethnicity, sex, body mass index and pre-existing conditions
H.RamachandranS.SongD
Sermorelin's larger molecular mass and linear chain create different stability considerations compared to Ipamorelin's compact pentapeptide scaffold
These sources note that heart palpitations are a possible side effect, especially when starting the medication or changing doses
Inhibition and induction of CYP enzymes in humans: an update